MiRNAs are important epigenetic players with tissue- and disease-specific effects. In this study, our aim was to investigate the putative differential expression of miRNAs in adrenal tissues from different forms of Cushing’s syndrome (CS). For this, miRNA-based next-generation sequencing was performed in adrenal tissues taken from patients with ACTH-independent cortisol-producing adrenocortical adenomas (CPA), from patients with ACTH-dependent pituitary Cushing’s disease (CD) after bilateral adrenalectomy, and from control subjects. A confirmatory QPCR was also performed in adrenals from patients with other CS subtypes, such as primary bilateral macronodular hyperplasia and ectopic CS. Sequencing revealed significant differences in the miRNA profiles of CD and CPA. QPCR revealed the upregulated expression of miR-1247-5p in CPA and PBMAH (log2 fold change > 2.5, p < 0.05). MiR-379-5p was found to be upregulated in PBMAH and CD (log2 fold change > 1.8, p < 0.05). Analyses of miR-1247-5p and miR-379-5p expression in the adrenals of mice which had been exposed to short-term ACTH stimulation showed no influence on the adrenal miRNA expression profiles. For miRNA-specific target prediction, RNA-seq data from the adrenals of CPA, PBMAH, and control samples were analyzed with different bioinformatic platforms. The analyses revealed that both miR-1247-5p and miR-379-5p target specific genes in the WNT signaling pathway. In conclusion, this study identified distinct adrenal miRNAs as being associated with CS subtypes.
Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare cause of Cushing’s syndrome. The study aimed to characterize changes in steroidogenesis in PBMAH through immunohistochemistry (IHC), transcriptomics and exome analysis with detailed clinical data assessment. Our cohort included 22 PBMAH patients who underwent adrenalectomy, and we investigated IHCs for five key steroidogenic enzymes (CYP11B1, CYP11B2, CYP17A1, HSD3B2 and CYB5A), covering the adrenocortical hormone secretion pathways. Unsupervised clustering of IHC staining identified three clusters: Cluster 1 exhibited low CYP11B1 and CYP17A1 expression, elevated HSD3B2 expression, smaller tumors, and included ARMC5 mutants. Cluster 2 showed higher enzyme staining for CYP11B1, CYP17A1 and CYB5A and included KDM1A mutants and female-only cases. Cluster 3 was characterized by slightly increased CYP11B2 staining and comprised of wild-type samples lacking ARMC5 and KDM1A variants. Exome sequencing identified steroidogenic pathway germline variants across the three clusters. Importantly, in Cluster 1, a higher burden of predicted damaging variants across various steroidogenic genes were found potentially leading to reduced enzyme staining through altered functions of the variant. However, this distinctive variant pattern was less evident in Cluster 2 and Cluster 3. Transcriptomics identified no differences between the clusters in terms of gene expression, hinting the influence of possible epigenetic factors on IHC. In summary, our study identified distinct groups in PBMAH based on their IHC staining patterns and highlights the importance for integrated molecular profiling for comprehensive characterization of heterogeneity in PBMAH.
Background: We performed a transcriptomic analysis of adrenal signaling pathways in various forms of endogenous Cushing’s syndrome (CS) to define areas of dysregulated and druggable targets.Methodology: Next-generation sequencing was performed on adrenal samples of patients with primary bilateral macronodular adrenal hyperplasia (PBMAH, n=10) and control adrenal samples (n=8). The validation groups included cortisol-producing adenoma (CPA, n=9) and samples from patients undergoing bilateral adrenalectomy for Cushing’s disease (BADX-CD, n=8). In vivo findings were further characterized using three adrenocortical cell-lines (NCI-H295R, CU-ACC2, MUC1).Results: Pathway mapping based on significant expression patterns identified PPARG (peroxisome proliferator-activated receptor gamma) pathway as the top hit. Quantitative PCR (QPCR) confirmed that PPARG (l2fc<-1.5) and related genes – FABP4 (l2fc<-5.5), PLIN1 (l2fc<-4.1) and ADIPOQ (l2fc<-3.3) – were significantly downregulated (p<0.005) in PBMAH. Significant downregulation of PPARG was also found in BADX-CD (l2fc<-1.9, p<0.0001) and CPA (l2fc<-1.4, p<0.0001). In vitro studies demonstrated that the PPARG activator rosiglitazone resulted in decreased cell viability in MUC1 and NCI-H295R (p<0.0001). There was also a significant reduction in the production of aldosterone, cortisol, and cortisone in NCI-H295R and in Dihydrotestosterone (DHT) in MUC1 (p<0.05), respectively.Outcome: This therapeutic effect was independent of the actions of ACTH, postulating a promising application of PPARG activation in endogenous hypercortisolism.
Background: MicroRNAs (miRNAs) have been identified to regulate gene expression in adrenal disorders. Objective: To investigate the effects of specific miRNAs on cortisol biosynthesis. Methods: Seven candidate miRNAs were transfected as mimics into steroidogenically active adrenocortical cell lines (NCI-H295R, HAC15, and CU-ACC1). Steroids were measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) and ELISA. Quantitative polymerase chain reaction was performed in all cell lines with additionally microarray analysis in HAC15 cells. Adrenal RNA-sequencing data from patients with Cushing's syndrome (CS, n = 10) and normal controls (n = 8) were analyzed to compare differentially expressed genes (DEGs) and enrichments. miRNA inhibitors were further used for validation Results: miR-486-5p and miR-144-3p mimics reduced cortisol levels by ∼60%-70% in NCI-H295R and HAC15 cells, and LC-MS/MS confirmed reduced steroidogenic metabolites. Both miR-486-5p and miR-144-3p mimics significantly inhibited CYP17A1 and CYP11B2 mRNA levels in NCI-H295R and HAC15 cells. Microarray analysis revealed the DEGs induced by miR-486-5p or miR-144-3p both predominantly enriched in “Metabolic Pathways,” consistent with enrichment in the CS adrenal dataset. Common metabolic genes (co-DEGs) between patient samples and miRNA mimic–treated cells exhibited complementary expression patterns. Cotransfection of the corresponding inhibitors attenuated cortisol suppression and metabolic gene changes. Protein–protein interaction analysis further clustered the miR-486-5p- and miR-144-3p-associated co-DEGs into lipid metabolism–related biological process. Conclusions: miR-486-5p and miR-144-3p suppress cortisol production in the human adrenocortical cell models of NCI-H295R and its derived HAC15 subclone and are associated with lipid metabolism–related networks, providing new insights into the molecular regulation of cortisol biosynthesis.
Introduction: Transcriptional regulation of gene expression by miRNAs is critical for the fine-tuning of adrenal stress response. However, its role in hypercortisolism has not been explored well. The study addresses this gap using adrenal samples of 3 patient groups from the German Cushings registry: Cortisol-Producing-Adenoma (CPA), Primary Bilateral Adrenal Hyperplasia (PBMAH) and controls (adrenal samples of patients with pheochromocytoma). Methods: Next generation sequencing based miRNA profiling and associated target analyses by QPCR were performed. Transcriptomic data of RNA-Seq were analysed and validated by QPCR. For pathway mapping bioinformatic tools (R, String, KEGG, Gprofiler) were used. Results: miRNA based NGS revealed 23 miRNAs to be differentially expressed between Cushing (PBMAH and CPA) and Controls. Of these, significantly upregulated miRNAs (n=6) were used for validation. Upregulated expression of hsa-miR-139-3p (l2fc>1.4), hsa-miR-1247-5p (l2fc>2.5) and hsa-miR-150-5p (l2fc>1.9) in PBMAH and CPA (vs Controls) could be confirmed by QPCR (P5; P<0.05) of dopamine (Drd2) and glutamate receptors (Gria4, Grin2a) in PBMAH. Validation of the pathway analysis is on-going. Conclusion: This study identifies a miRNA-target gene network in possible steroid biosynthesis dysfunctions in adrenals of patients with Cushings syndrome. Additionally, potential changes in neuronal synaptic pathways in PBMAH were identified.